Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients
Inside Liposarcoma Clinical Trials: Patient Experiences Shared While Undergoing Clinical Trials
1 other identifier
observational
500
1 country
1
Brief Summary
The study seeks to delve into the firsthand experiences of patients diagnosed with liposarcoma who partake in a separate clinical research featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. By joining this clinical study, individuals have the unique opportunity to contribute to the betterment of future liposarcoma patients and play an active role in advancing medical research.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 8, 2023
CompletedFirst Posted
Study publicly available on registry
September 15, 2023
CompletedStudy Start
First participant enrolled
October 1, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2026
ExpectedSeptember 15, 2023
September 1, 2023
1 year
September 8, 2023
September 8, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Number of patients who decide to participate in a liposarcoma clinical study
3 months
Rate of patients who remain in liposarcoma clinical study to trial completion
12 months
Eligibility Criteria
People with liposarcoma who are actively considering enrolling in an observational clinical trial, but have not yet completed enrollment and randomization.
You may qualify if:
- Patient has self-identified as planning to enroll in a clinical research
- Patient has been diagnosed with liposarcoma
- Patient is a minimum of 18 years or older
You may not qualify if:
- Patient does not understand, sign, and return consent form
- Inability to perform regular electronic reporting
- Patient is pregnant
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Power Life Sciences
San Francisco, California, 94107, United States
Related Publications (3)
Chen M, Yang J, Zhu L, Zhou C, Zhao H. Primary intrathoracic liposarcoma: a clinicopathologic study and prognostic analysis of 23 cases. J Cardiothorac Surg. 2014 Jul 4;9:119. doi: 10.1186/1749-8090-9-119.
PMID: 24993036BACKGROUNDMarino-Enriquez A, Hornick JL, Dal Cin P, Cibas ES, Qian X. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. Cancer Cytopathol. 2014 Feb;122(2):128-37. doi: 10.1002/cncy.21362. Epub 2013 Nov 12.
PMID: 24227706BACKGROUNDRossouw DJ, Cinti S, Dickersin GR. Liposarcoma. An ultrastructural study of 15 cases. Am J Clin Pathol. 1986 Jun;85(6):649-67. doi: 10.1093/ajcp/85.6.649.
PMID: 3706206BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Michael B Gill
Power Life Sciences
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CROSSOVER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 8, 2023
First Posted
September 15, 2023
Study Start
October 1, 2024
Primary Completion
October 1, 2025
Study Completion (Estimated)
October 1, 2026
Last Updated
September 15, 2023
Record last verified: 2023-09